GlassScriptPhysician profile
Jamie K Waselenko
NPI 1710911847
$1,931.63
in general payments reported to CMS, 2019-2025
37 companies · $203 in 2025
The $203 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,277 · 2020: $334 · 2021: $13.87 · 2022: $35.53 · 2024: $68.27 · 2025: $203.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $271.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $271.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $253.37 | 2019-2020 | |
| Pharmacyclics LLC, An Abbvie Company | $138.45 | 2019-2021 | |
| Pfizer INC. | $136.40 | 2019-2025 | |
| Jazz Pharmaceuticals INC. | $127.47 | 2019 | |
| Janssen Biotech, INC. | $97.51 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $85.48 | 2019-2020 | |
| Foundation Medicine, INC. | $84.20 | 2019-2022 | |
| Genzyme Corporation | $68.73 | 2019-2022 | |
| Pharmacosmos Therapeutics INC. | $68.28 | 2024-2025 | Monoferric |
| E.R. Squibb & Sons, L.L.C. | $62.45 | 2019 | |
| Daiichi Sankyo INC. | $57.51 | 2019-2024 | Injectafer |
| Amgen INC. | $56.30 | 2019 | |
| Astellas Pharma US INC | $56.29 | 2019-2020 | |
| Stemline Therapeutics INC. | $56.24 | 2024-2025 | Orserdu |
| Bayer Healthcare Pharmaceuticals INC. | $52.19 | 2019-2020 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $50.92 | 2019 | |
| Incyte Corporation | $45.93 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $42.99 | 2020-2025 | Enhertu |
| Celgene Corporation | $39.10 | 2019 | |
| Eisai INC. | $37.17 | 2019-2020 | |
| Emd Serono, INC. | $36.67 | 2019-2020 | |
| Verastem, INC. | $30.87 | 2019-2020 | |
| Lilly USA, LLC | $28.63 | 2019-2025 | Jaypirca, Verzenio |
| Genentech USA, INC. | $24.10 | 2019 | |
| Abbott Laboratories | $19.68 | 2019 | |
| Dendreon Pharmaceuticals LLC | $19.58 | 2019 | |
| Gilead Sciences, INC. | $18.62 | 2025 | Trodelvy |
| Clovis Oncology, INC. | $17.81 | 2019 | |
| Dova Pharmaceuticals | $17.23 | 2019 | |
| Mylan Institutional INC. | $15.68 | 2019 | |
| Adaptive Biotechnologies Corporation | $14.50 | 2025 | Clonoseq |
| Array Biopharma INC | $13.50 | 2020 | |
| Lexicon Pharmaceuticals, INC. | $12.03 | 2020 | |
| Rigel Pharmaceuticals, INC. | $11.86 | 2019 | |
| Seagen INC. | $11.67 | 2020 | |
| Glaxosmithkline, LLC. | $11.29 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $10.93 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jamie Waselenko listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.